Prostate Cancer PSA Screening and Management Guidelines

Screening Initiation

• Average‑risk men should engage in shared decision‑making about PSA screening at age 50 when life expectancy is ≥10 years. (Evidence level: moderate) 2
• Obtain a baseline PSA at age 40 to improve prediction of future prostate cancer risk, outperforming family history or race alone. (Evidence level: moderate) 3
• PSA testing in men aged 40‑49 is more specific for cancer because benign prostatic hyperplasia is uncommon in this age group. (Evidence level: moderate) 3

High‑Risk Populations

• African‑American men should begin PSA screening at age 45 because they have ~75 % higher incidence and >2‑fold higher mortality than non‑Hispanic White men. (Evidence level: strong) 4
• Men with one first‑degree relative diagnosed before age 65 should start screening at age 45. (Evidence level: strong) 4
• Men with multiple first‑degree relatives diagnosed before age 65 should start at age 40. (Evidence level: strong) 4
• For men who start at age 40 and have a PSA < 1.0 ng/mL, no further testing is required until age 45. (Evidence level: moderate) 1

PSA‑Based Screening Intervals

• Biennial screening (every 2 years) reduces the diagnosis of advanced prostate cancer by 43 % compared with a 4‑year interval, while increasing detection of low‑risk disease by 46 %. (Evidence level: moderate) 1
• Screening every 2 years cuts total PSA tests by 59 % and false‑positive results by 50 % versus annual screening. (Evidence level: moderate) 1

Diagnostic Thresholds and Cancer Probability

• PSA 0–2 ng/mL → ~1 % probability of prostate cancer. (Evidence level: strong) 5
• PSA 2–4 ng/mL → 15–25 % likelihood of biopsy‑detectable cancer. (Evidence level: strong) 3
• PSA 4–10 ng/mL → 17–32 % cancer probability; if cancer is present, ~70 % are organ‑confined. (Evidence level: strong) 2
• PSA > 10 ng/mL → >50 % probability of cancer; ~50 % of those are organ‑confined. (Evidence level: strong) 2

Lymph‑Node Metastasis Risk

Staging Workup Based on PSA

• Bone scan is generally unnecessary when PSA < 20 ng/mL unless clinical findings suggest bone involvement. (Evidence level: strong) 2
• Perform bone scan if Gleason ≥ 8 or stage T3 disease even with PSA < 10 ng/mL. (Evidence level: strong) 2

• Mandatory bone scan at PSA ≥ 20 ng/mL. (Evidence level: strong) 2

• Cross‑sectional imaging (CT/MRI) is usually not required when PSA < 25 ng/mL. (Evidence level: strong) 2

• Consider CT/MRI when PSA > 20 ng/mL, Gleason ≥ 8, or locally advanced disease. (Evidence level: strong) 2

• Pelvic lymph‑node dissection is not needed if PSA < 10 ng/mL and Gleason ≤ 6. (Evidence level: strong) 2
• Dissection is required for PSA ≥ 10 ng/mL or Gleason > 6. (Evidence level: strong) 2

Individualized Assessment for PSA 2.5–4.0 ng/mL

• African‑American race, family history, older age, abnormal DRE, and prior negative biopsy (all moderate‑evidence). (Evidence level: moderate) 1
• Use the Prostate Cancer Prevention Trial (PCPT) Risk Calculator to estimate the probability of high‑grade disease. (Evidence level: moderate) 1

Adjunctive PSA‑Based Tests (PSA 3–10 ng/mL)

• Percent free PSA (< 25 %) raises suspicion for cancer. (Evidence level: strong) 4
• 4Kscore may refine selection for biopsy. (Evidence level: moderate) 4
• Prostate Health Index (phi) is useful in biopsy‑naïve patients. (Evidence level: moderate) 4
• PCA3 is considered after at least one prior negative biopsy. (Evidence level: moderate) 4

PSA Velocity (PSAV)

• PSAV assessment requires ≥ 3 PSA measurements over ≥ 18 months. (Evidence level: moderate) 3
• PSAV > 0.35 ng/mL/year (when PSA < 4 ng/mL) warrants closer surveillance. (Evidence level: moderate) 3
• Age‑adjusted PSAV thresholds: 0.25 ng/mL/year (ages 40‑59), 0.5 ng/mL/year (ages 60‑69), 0.75 ng/mL/year (≥ 70). (Evidence level: moderate) 3
• PSAV > 2.0 ng/mL/year in the year preceding diagnosis confers an ~10‑fold higher risk of prostate‑cancer‑specific death after radical prostatectomy. (Evidence level: strong) 2

Post‑Treatment PSA Monitoring

After Radical Prostatectomy

• PSA should become undetectable (< 0.1 ng/mL). (Evidence level: strong) 2
• Biochemical recurrence is defined as PSA ≥ 0.2 ng/mL on two consecutive tests. (Evidence level: strong) 2
• 10‑year recurrence risk: ~10 % if pre‑operative PSA < 2.6 ng/mL; ~20 % if 2.6–10 ng/mL; ~50 % if > 10 ng/mL. (Evidence level: strong) 2

When to Stop Screening

• Routine PSA screening should be discontinued at age 70 for most men (NCCN). (Evidence level: strong) 4
• Screening may continue beyond age 70 only in exceptionally healthy men with minimal comorbidities, prior elevated PSA, and life expectancy >10–15 years. (Evidence level: moderate) 4
• Men aged 60 with PSA < 1.0 ng/mL have a 0.5 % risk of metastasis and 0.2 % risk of prostate‑cancer death; screening can safely stop. (Evidence level: moderate) 1
• Men ≥ 75 with PSA < 3.0 ng/mL are unlikely to die from prostate cancer and may discontinue screening. (Evidence level: moderate) 1
• Never screen men with life expectancy < 10 years, as mortality benefit requires >10 years to manifest. (Evidence level: strong) 1

Mandatory Shared Decision‑Making

• PSA screening must be preceded by an informed discussion of benefits and harms (NCCN). (Evidence level: strong) 4
• Benefit: ~20–25 % relative reduction in prostate‑cancer mortality (≈1.3 fewer deaths per 1,000 men screened over 13 years). (Evidence level: moderate) 1
• Harms: false‑positive results → unnecessary biopsies; overdiagnosis of indolent cancers; treatment complications (erectile dysfunction, urinary incontinence). (Evidence level: strong) 4
• No improvement in all‑cause mortality has been demonstrated. (Evidence level: strong) 1

Factors Affecting PSA Interpretation

• 5α‑reductase inhibitors (finasteride, dutasteride) lower PSA by ~50 %; multiply measured PSA by 2.3 to estimate true value. (Evidence level: strong) 8
• Urinary catheterization, prostatitis, and benign prostatic hyperplasia can transiently elevate PSA. (Evidence level: strong) 8
• Laboratory PSA variability can be 20–25 %; use the same assay for longitudinal monitoring. (Evidence level: moderate) 3
• Dialysis increases the proportion of free PSA due to altered renal clearance. (Evidence level: moderate) 8